文献速递免疫规划妇幼与学校卫生

2018-2022年阿富汗Rotarix接种后肠套叠的上市后监测

Post-marketing surveillance of intussusception after Rotarix administration in Afghanistan, 2018-2022.
PubMed 文献 · Vaccine · 2024-02-26

2018年5月至2022年3月在阿富汗四个哨点开展多中心前瞻性主动医院监测,采用Brighton 1级标准诊断肠套叠,共识别468例12月龄以下肠套叠病例,其中264例年龄28-245天且接种状态确认者纳入自控病例系列分析。结果显示Rotarix接种后1-21天肠套叠风险未见升高,但病例中手术和死亡比例较高。

要点

  • 阿富汗四个哨点前瞻性监测发现468例12月龄以下肠套叠病例,264例纳入自控病例系列分析。
  • 首剂后1-21天相对发生率为1.1(95%CI 0.4-3.4),第二剂后为0.6(95%CI 0.3-1.2),均未见风险升高。
  • 98%病例需手术,手术者中59%需肠切除,7%病例死亡。

核心结论

  • Rotarix接种与肠套叠风险升高无关,支持继续在阿富汗免疫规划中使用。
  • 阿富汗婴儿肠套叠导致的死亡和肠切除比例较高。

研究设计与样本

  • 2018年5月至2022年3月在阿富汗四个哨点开展多中心前瞻性主动医院监测。
  • 采用Brighton 1级标准诊断肠套叠,通过查看接种卡核实接种状态。
  • 采用自控病例系列方法比较每剂Rotarix接种后1-21天与非风险期的肠套叠发生率。
  • 共识别468例12月龄以下肠套叠病例,其中264例年龄28-245天且接种状态确认者纳入自控病例系列分析。

主要发现

  • 98%病例需手术治疗,手术者中59%需肠切除,7%病例死亡。
  • 86%病例在肠套叠症状出现前已接种第一剂Rotarix,69%已接种第二剂。
  • 首剂后1-7天相对发生率为0.9(95%CI 0.1-7.5),8-21天为1.3(95%CI 0.4-4.2),1-21天为1.1(95%CI 0.4-3.4)。
  • 第二剂后1-7天相对发生率为0.2(95%CI 0.3-1.8),8-21天为0.7(95%CI 0.3-1.5),1-21天为0.6(95%CI 0.3-1.2)。

关键数值与推荐

  • 肠套叠诊断采用Brighton 1级标准。
  • 自控病例系列分析比较接种后1-21天与非风险期的肠套叠发生率。

临床怎么用

  • 作者认为Rotarix接种与肠套叠风险升高无关,支持继续在阿富汗免疫规划中使用。
  • 作者指出阿富汗婴儿肠套叠导致的死亡和肠切除比例较高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In January 2018, Afghanistan introduced the monovalent oral rotavirus vaccine (Rotarix) nationwide, administered as a 2-dose series at six and ten weeks of age. We describe characteristics of intussusception cases and assess potential intussusception risk associated with Rotarix vaccination in Afghan infants. METHODS: Multi-center prospective active hospital-based surveillance for intussusception was conducted from May 2018 to March 2022 in four sentinel sites in Afghanistan. We applied the Brighton Level 1 criteria for intussusception and verified vaccination status by reviewing vaccine cards. We used the self-controlled case series (SCCS) methodology to compare intussusception incidence in the 1 to 21 days after each dose of Rotarix vaccination against non-risk periods. RESULTS: A total of 468 intussusception cases were identified in infants under 12 months, with 264 cases aged between 28 and 245 days having confirmed vaccination status contributing to the SCCS analysis. Most case-patients (98 %) required surgery for treatment, and over half (59 %) of those who underwent surgery required intestinal resection. Nineteen (7 %) case-patients died. Eighty-six percent of case-patients received the first dose of Rotarix, and 69 % received the second dose before intussusception symptom onset. There was no increased risk of intussusception in the 1-7 days (relative incidence: 0.9, 95 % CI: 0.1, 7.5), 8-21 days (1.3, 95 % CI: 0.4, 4.2), or 1-21 days (1.1, 95 % CI: 0.4, 3.4) following receipt of the first dose or in the 1-7 days (0.2, 95 % CI: 0.3, 1.8), 8-21 days (0.7, 95 % CI: 0.3, 1.5), or 1-21 days (0.6, 95 % CI: 0.3, 1.2) following the second dose. CONCLUSION: Rotarix vaccination was not associated with an increased intussusception risk, supporting its continued use in Afghanistan's immunization program. However, there was a high level of death and resection due to intussusception among Afghan infants.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Anwari P, Burnett E, Chavers TP, et al. Post-marketing surveillance of intussusception after Rotarix administration in Afghanistan, 2018-2022. Vaccine. 2024. PMID: 38413278. doi:10.1016/j.vaccine.2024.02.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。